Research access and current care are different paths.

Prepared September 14, 2026 · Publisher review required · No clinician review claimed

An interest in retatrutide does not establish eligibility for a research program—or identify an appropriate treatment today.

Clinical research

ClinicalTrials.gov provides original study records. Read the current record and discuss study participation with a healthcare professional. A listing is not a federal endorsement, an assurance that a particular site is recruiting, or a guarantee of eligibility. S06: Finding a Clinical Trial S07: Search retatrutide trial records

Expanded access

FDA explains expanded access as a distinct pathway involving an investigational product outside a clinical trial in certain circumstances. Lilly publishes retatrutide-specific access information. Read those original sources; this site does not accept applications, screen eligibility or obtain medicine. S09: Expanded Access S08: Is there an expanded access program for retatrutide?

Ordinary commercial supply

FDA currently states retatrutide is not a component of an approved drug and cannot be used in compounding under federal law. An online vendor’s terminology or a directory listing should not be treated as proof of lawful supply. S01: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss

Care available now

A separate, clearly labeled directory section can help readers explore provider information for current healthcare concerns. It must not imply that a listed provider can supply retatrutide or that a different treatment is medically interchangeable. Clinical decisions belong to the treating clinician and patient.

RetaRegister is an information newsletter. Subscribing does not create an appointment, reserve medication, confer trial eligibility or advance an access application.